Based in Delaware, CD Diagnostics is focused on the development of immunoassays and biomarker testing, which will help in taking treatment decisions that improve patient outcomes.

CD Diagnostics is primarily engaged in analyzing biomarker profiles for various clinical conditions in synovial fluid, in addition to creating diagnostic assays.

Synovial fluid is a viscous fluid that reduces friction between articular cartilage.

In 2012, Zimmer and CD Diagnostics partnered to co-develop and market diagnostics in the field of musculoskeletal healthcare.

Under the original agreement, Zimmer Biomet marketed the Synovasure periprosthetic joint infection (PJI) test.

CD Diagnostics scientific founder Carl Deirmengian said: "I formed CD Diagnostics to solve the frustrating problem of diagnosing PJI and the complications associated with misdiagnosis, including the pain and incremental costs-of-care following joint replacement surgery.

“As a leader and visionary in musculoskeletal healthcare, Zimmer Biomet is the ideal partner to leverage our expertise in biomarker detection and immunoassay development, and to elevate the value of diagnostics in the treatment of musculoskeletal conditions.”

Zimmer Biomet joint reconstruction group president Dan Williamson said: "Our acquisition of CD Diagnostics cements our leadership and competitive advantage in musculoskeletal diagnostics, strengthens our Signature Solutions offering, and advances our mission to provide comprehensive musculoskeletal healthcare.”

In June, Zimmer Biomet agreed to acquire medical device firm LDR Holding for about $1bn.

Established in 2000, LDR is engaged in the design and commercialization of novel surgical technologies to treat patients with spine disorders.

Image: Zimmer Biomet has acquired CD Diagnostics that develops immunoassays. Photo: courtesy of adamr / FreeDigitalPhotos.net.